Seres Therapeutics Inc (MCRB)
$1.32
Performance
- $1.29$1.43$1.32
2.25%
Downside
Day's Volatility :9.76%
Upside
7.69%
- $0.54$5.29$1.32
59.09%
Downside
52 Weeks Volatility :89.79%
Upside
75.05%
Returns
| Period | Seres Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 64.85% | 6.5% | 0.0% |
6 Months | 18.26% | 7.1% | 0.0% |
1 Year | -69.57% | 9.8% | 0.0% |
3 Years | -82.29% | 14.2% | -20.2% |
Highlights
Market Capitalization | 206.7M |
Book Value | - $0.39 |
Earnings Per Share (EPS) | -0.59 |
PEG Ratio | -0.11 |
Wall Street Target Price | 3.45 |
Profit Margin | -65.18% |
Operating Margin TTM | -60.7% |
Return On Assets TTM | -15.74% |
Return On Equity TTM | -538.57% |
Revenue TTM | 126.8M |
Revenue Per Share TTM | 0.95 |
Quarterly Revenue Growth YOY | -93.4% |
Gross Profit TTM | -165.8M |
EBITDA | -70.6M |
Diluted Eps TTM | -0.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.04 |
EPS Estimate Next Year | -0.77 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Next Quarter | -0.31 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 161.36%
Technicals Summary
Sell
Neutral
Buy
Seres Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Seres Therapeutics Inc | 81.12% | 18.26% | -69.57% | -82.29% | -52.28% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Seres Therapeutics Inc | NA | NA | -0.11 | -1.04 | -5.39 | -0.16 | NA | -0.39 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Seres Therapeutics Inc | Buy | $206.7M | -52.28% | NA | -65.18% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Seres Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 126.47M → 64.0K (in $), with an average decrease of 89.6% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -47.85M → -40.13M (in $), with an average increase of 9.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 131.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 268.8%
Institutional Holdings
Flagship Ventures Management, Inc.
15.26%FMR Inc
14.96%BlackRock Inc
4.51%Vanguard Group Inc
4.45%Hudson Bay Capital Management LP
3.58%Geode Capital Management, LLC
1.41%
Company Information
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Organization | Seres Therapeutics Inc |
Employees | 233 |
CEO | Mr. Eric D. Shaff M.B.A. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$1.32
-2.94%
Keyarch Acquisition Corp
$1.32
-2.94%
Connexa Sports Technologies Inc
$1.32
-2.94%
Us Value Etf
$1.32
-2.94%
First Wave Biopharma Inc
$1.32
-2.94%
Global X Msci Next Emerging
$1.32
-2.94%
Fat Projects Acquisition Corp
$1.32
-2.94%
Capital Link Global Fintech
$1.32
-2.94%
Applied Uv Inc
$1.32
-2.94%